

Ref. No: 2513  
Date: 16/04/26  
Subject: Head and Neck cancer

## REQUEST

Q1. Does your Trust treat patients for head and neck cancer (Squamous cell carcinoma)? If no, which Trust do you refer patients onto for treatment?

Q2. Within your trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following?

- Surgery only
- Radiotherapy only
- Surgery + Radiotherapy
- Carboplatin (only or in combination with 5-FU)
- Cisplatin (only or in combination with 5-FU)
- Cetuximab with/without chemotherapy
- Cetuximab with radiotherapy
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Nivolumab
- Docetaxel (only or in combination with 5-FU)
- Fluorouracil (5FU) monotherapy
- Any other chemotherapy (without radiotherapy)
- Any other chemotherapy (with radiotherapy)

Q3. Could you please provide the number of patients treated in the past 3 months with the following agents for metastatic head and neck cancer (squamous cell carcinoma)?

- Cetuximab with/without chemotherapy
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Nivolumab
- Docetaxel (only or in combination with 5-FU)
- Any other chemotherapy (without radiotherapy)

- Any other chemotherapy (with radiotherapy)

Q4. How many patients who received Pembrolizumab for head and neck cancer (squamous cell carcinoma) in the last 3 months, received:

- Treatment every 3 weeks (200mg, Q3W)
- Treatment every 6 weeks (400mg, Q6W)

Q5. Does your trust participate in any clinical trials for head and neck cancer? If so, please provide the trial details and number of patients who are taking part.

## RESPONSE

MWL does not treat Head and Neck cancers.

Surgery is undertaken at Aintree hospital.

<https://www.uhliverpool.nhs.uk/>